INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Recruiting

Phase 2

Phase 3

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCINBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Sponsor:

Inhibrx Biosciences, Inc

Code:

NCT06295731

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

INBRX-106

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Inhibrx Biosciences, Inc on 2025-03-25.